Fundraising FoxCure Ventures — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Director & Chief Scientific Advisor)inCam Gallagher(President & Chief Executive Officer)inJohn Maroney(Executive Officer, Director)in
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)in
Board seatAnnie Mitsak· per SEC Form D
Co-investorsMission Bay CapitalMission Biocapital
BiotechBoston, US
Ronald D. Seidel, III(Executive Officer, Director)David Fallace(Director)
BoardCameron Gallagher(Director)Rodolfo Chaparro(Director)inAndrew King(Executive Officer)in
Board seatDavid FallaceLou Tartaglia· per SEC Form D
Triton Therapeutics is a clinical-stage biotechnology company developing first-in-class medicines for autoimmune and fibrotic diseases.
BiotechHealthtechStamford, US
BoardAnnie Mitsak(Director)inTimothy Shannon(Director)Elena Grigoryeva(Director)Paul Fonteyne(Executive Officer, Director)in
Co-investorsCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.